zyrova-stemi without smurfs-a4

2
Brought to you by: Rosuvastatin 5,10 & 20 mg Tablets Reference: Figtree et al. (2021). Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet (Online First, March 09) https://doi.org/10.1016/S0140-6736(21)00272-5 EMB/MED/SFF/CVS/21/03/EM/04 SMuRFs, standard modifiable cardiovascular risk factors STEMI without SMuRFs

Upload: others

Post on 16-Oct-2021

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Zyrova-STEMI without SMURFs-A4

Brought to you by:

Rosuvastatin 5,10 & 20 mg Tablets

Reference: Figtree et al. (2021). Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet (Online First, March 09)

https://doi.org/10.1016/S0140-6736(21)00272-5

EMB/MED/SFF/CVS/21/03/EM/04 SMuRFs, standard modifiable cardiovascular risk factors

STEMI withoutSMuRFs

Page 2: Zyrova-STEMI without SMURFs-A4

FOR FURTHER INFORMATION, PLEASE CONTACT:

INTERNATIONAL DIVISION

Nr. Vaishnodevi Circle, Sarkhej - Gandhinagar Highway, Ahmedabad - 382481. Phone : +91-079-48040000 Website : www.zyduscadila.com

STEMI commonly occurs in the absence of four common CV risk factors:

Hypertension

Hypercholesterolemia

Current Smoking

DiabetesSuch patients have worse

outcomes as compared to those who have at least

one SMuRF

Patients without SMuRFs lack modifiable targets for therapy

0

2

4

6

8

10

12

14

16

18

20

MEN WOMEN

9.3

17.6

6.1

11.1

N = 7064N = 34600

N = 18220

N = 2164

Patients without SMuRFs Patients with at least one SMuRF

All

caus

e m

ort

alit

y (%

of

pat

ient

s)

The increased mortality rates can be attenuated after use of guideline-indicated treatments